# Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

> **NCT00047827** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 2 (actual)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** Micafungin
- **DRUG:** Liposomal Amphotericin B

## Key facts

- **NCT ID:** NCT00047827
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** 2003-02
- **Final completion:** 2003-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Inadequate enrollment
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047827, "Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00047827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*